Lumexa Imaging Holdings heads into the week after its Q1 print with short sellers retreating sharply — and a stock that's finally starting to recover from a bruising March.
The clearest story this week is the short covering. SI % FF collapsed from roughly 21% to just under 14% in the two sessions straddling the Q1 release on May 12 — a drop of more than one-third of the float in barely 48 hours. That's not a gradual unwind; it's shorts exiting into earnings news. The Q1 numbers gave them reason to leave: adjusted EPS of $0.18 beat the $0.12 consensus by 50%, and revenue of $252.5M came in ahead of the $251M estimate. Full-year guidance was narrowed rather than cut, with adj. EPS now guided to $0.71–$0.77 against a $0.73 Street estimate. Not a blowout, but enough to wrong-foot a short base that had been building through April. The ORTEX short score has fallen to 65.2 from a peak of 70.3 on May 6, tracking that unwind in real time.
The borrow market tells a more complicated story. Cost to borrow surged nearly 400% in one week — from around 0.85% to 4.27% — even as shorts were covering. That's an unusual combination. It points to a scramble to secure borrows into the earnings date, likely by traders running hedges or initiating fresh positions, followed by an abrupt reversal as the beat cleared the air. The ORTEX short score's still-elevated reading (65+) reflects that borrow stress hasn't fully faded. Availability is relatively loose at 165% of current short interest, suggesting the lending pool has capacity — but the recent CTB spike shows demand was real, even briefly.
The Street arrived at this earnings with mixed conviction. Barclays maintained its Overweight rating in April but cut its price target sharply from $23 to $15 — a sign that the firm remained constructive on the name but was trimming expectations after the stock's March collapse (the stock fell nearly 30% in a single session following the prior quarter's release). Raymond James had earlier upgraded to Strong Buy with a $23 target. At $10.50 today, with the mean target around $18.85, the implied upside is substantial — though it must be noted those targets were set before the Q1 beat and some may be updated in the coming days. Valuation looks undemanding: EV/EBITDA at roughly 7.9x and a P/E of 13.4x are well below typical healthcare services multiples, while the P/B of 1.4x gives little away on balance sheet.
The ownership structure is worth noting. Welsh, Carson, Anderson & Stowe holds nearly 70% of shares outstanding — an extraordinary concentration for a listed company. With a free float of only around 22.2 million shares against ~96 million total, the effective trading universe is small. That thinness amplifies moves in both directions: the March 30% drop and this week's covering rally are both easier to understand in that context. Emerald Advisers added 336,000 shares in Q1, a modest but positive signal from a long-only manager.
The next confirmed event is May 18 — a second earnings-adjacent date in the data, suggesting either a formal earnings call or investor update. With shorts having just covered heavily and borrow costs elevated but easing, what matters now is whether the guidance narrowing and EPS beat can sustain the stock's 8% weekly gain or whether sellers emerge as the dust settles post-cover.
See the live data behind this article on ORTEX.
Open LMRI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
